Go Pro
→ Your book attached (From Profits Run) (Ad)tc pixel

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Compare
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CalciMedica Inc. stock logo
CALC
CalciMedica
$0.71
-3.9%		$0.83
$0.46
▼
$7.20
$11.71M0.91328,126 shs162,575 shs
Intensity Therapeutics Inc. stock logo
INTS
Intensity Therapeutics
$4.25
+1.2%		$4.25
$3.51
▼
$43.50
$11.35M2.7628,458 shs12,398 shs
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
$2.56
+0.8%		$2.57
$1.76
▼
$3.01
$11.26M-0.3822,075 shs13,442 shs
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$1.12
$1.06
$0.31
▼
$1.50
$2.91M1.13,233 shs4 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CalciMedica Inc. stock logo
CALC
CalciMedica
-3.91%-15.24%-25.52%+13.20%-76.31%
Intensity Therapeutics Inc. stock logo
INTS
Intensity Therapeutics
+1.19%+4.94%-11.09%-16.50%-37.50%
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
+0.79%+0.04%+0.39%+4.49%+5.35%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
0.00%-5.08%0.00%+10.89%+49.33%
CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
CalciMedica Inc. stock logo
CALC
CalciMedica
$0.71
-3.9%		$0.83
$0.46
▼
$7.20
$11.71M0.91328,126 shs162,575 shs
Intensity Therapeutics Inc. stock logo
INTS
Intensity Therapeutics
$4.25
+1.2%		$4.25
$3.51
▼
$43.50
$11.35M2.7628,458 shs12,398 shs
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
$2.56
+0.8%		$2.57
$1.76
▼
$3.01
$11.26M-0.3822,075 shs13,442 shs
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$1.12
$1.06
$0.31
▼
$1.50
$2.91M1.13,233 shs4 shs
10 Stocks Powering The Next AI Boom Cover
10 Stocks Powering The Next AI Boom

The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.

Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
CalciMedica Inc. stock logo
CALC
CalciMedica
-3.91%-15.24%-25.52%+13.20%-76.31%
Intensity Therapeutics Inc. stock logo
INTS
Intensity Therapeutics
+1.19%+4.94%-11.09%-16.50%-37.50%
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
+0.79%+0.04%+0.39%+4.49%+5.35%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
0.00%-5.08%0.00%+10.89%+49.33%
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
CalciMedica Inc. stock logo
CALC
CalciMedica
2.00
Hold$10.001,304.49% Upside
Intensity Therapeutics Inc. stock logo
INTS
Intensity Therapeutics
2.67
Moderate Buy$37.50782.35% Upside
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
2.00
Hold$10.00290.63% Upside
Vaccinex, Inc. stock logo
VCNX
Vaccinex
0.00
N/AN/AN/A

Current Analyst Ratings Breakdown

Latest VCNX, INTS, CALC, and KPRX Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
7/29/2026
CalciMedica Inc. stock logo
CALC
CalciMedica
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/29/2026
CalciMedica Inc. stock logo
CALC
CalciMedica
HC Wainwright logo
HC Wainwright
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingNeutral
7/21/2026
Intensity Therapeutics Inc. stock logo
INTS
Intensity Therapeutics
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
7/14/2026
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
7/7/2026
CalciMedica Inc. stock logo
CALC
CalciMedica
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSell (E+)
6/26/2026
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
DowngradeSell (D-) ➝ Sell (E+)
6/11/2026
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
Weiss Ratings logo
Weiss Ratings
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
UpgradeSell (E+) ➝ Sell (D-)
5/20/2026
Intensity Therapeutics Inc. stock logo
INTS
Intensity Therapeutics
Benchmark Co. logo
Benchmark
Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating
Reiterated RatingSpeculative Buy
(Data available from 8/7/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
CalciMedica Inc. stock logo
CALC
CalciMedica
N/AN/AN/AN/A($0.46) per shareN/A
Intensity Therapeutics Inc. stock logo
INTS
Intensity Therapeutics
N/AN/AN/AN/A$4.94 per shareN/A
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
$16.02M0.71N/AN/A$4.38 per share0.58
Vaccinex, Inc. stock logo
VCNX
Vaccinex
$388K7.51N/AN/A($2.59) per share-0.43
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
CalciMedica Inc. stock logo
CALC
CalciMedica
-$29.56M-$1.31N/AN/AN/AN/A-863.40%-144.33%8/11/2026 (Estimated)
Intensity Therapeutics Inc. stock logo
INTS
Intensity Therapeutics
-$11.61M-$5.71N/AN/AN/AN/A-136.82%-105.82%8/11/2026 (Estimated)
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
-$10.84M-$2.71N/AN/AN/AN/A-59.30%-41.23%8/7/2026 (Estimated)
Vaccinex, Inc. stock logo
VCNX
Vaccinex
-$20.25M-$48.27N/AN/AN/AN/AN/A-383.58%8/10/2026 (Estimated)

Latest VCNX, INTS, CALC, and KPRX Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/11/2026N/A
CalciMedica Inc. stock logo
CALC
CalciMedica
-$0.33N/AN/AN/AN/AN/A
8/11/2026Q2 2026
Intensity Therapeutics Inc. stock logo
INTS
Intensity Therapeutics
-$0.8725N/AN/AN/AN/AN/A
8/10/2026N/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
-$73.0380N/AN/AN/A$0.63 millionN/A
8/7/2026Q2 2026
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
-$0.47-$0.34+$0.13-$0.34N/AN/A
5/8/2026Q1 2026
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
-$0.58-$0.58N/A-$0.58$1.50 millionN/A
5/7/2026Q1 2026
Intensity Therapeutics Inc. stock logo
INTS
Intensity Therapeutics
-$1.0850-$0.96+$0.1250-$0.96N/AN/A
CompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive Growth
CalciMedica Inc. stock logo
CALC
CalciMedica
N/AN/AN/AN/AN/A
Intensity Therapeutics Inc. stock logo
INTS
Intensity Therapeutics
N/AN/AN/AN/AN/A
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
N/AN/AN/AN/AN/A
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
CalciMedica Inc. stock logo
CALC
CalciMedica
N/A
1.61
1.61
Intensity Therapeutics Inc. stock logo
INTS
Intensity Therapeutics
0.01
4.86
4.86
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
N/A
6.68
6.68
Vaccinex, Inc. stock logo
VCNX
Vaccinex
N/A
0.77
0.77

Institutional Ownership

CompanyInstitutional Ownership
CalciMedica Inc. stock logo
CALC
CalciMedica
N/A
Intensity Therapeutics Inc. stock logo
INTS
Intensity Therapeutics
3.74%
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
76.97%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
50.11%

Insider Ownership

CompanyInsider Ownership
CalciMedica Inc. stock logo
CALC
CalciMedica
28.25%
Intensity Therapeutics Inc. stock logo
INTS
Intensity Therapeutics
7.60%
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
0.52%
Vaccinex, Inc. stock logo
VCNX
Vaccinex
51.50%
CompanyEmployeesShares OutstandingFree FloatOptionable
CalciMedica Inc. stock logo
CALC
CalciMedica
3015.80 million11.34 millionNo Data
Intensity Therapeutics Inc. stock logo
INTS
Intensity Therapeutics
2,0212.70 million2.50 millionNot Optionable
Kiora Pharmaceuticals, Inc. stock logo
KPRX
Kiora Pharmaceuticals
104.43 million4.41 millionNot Optionable
Vaccinex, Inc. stock logo
VCNX
Vaccinex
402.60 million1.26 millionNo Data

Recent News About These Companies

Vaccinex to Report New Biomarker Data and Plans for Phase 2B Clinical Trial of Pepinemab in AD at the Alzheimer's Association International Conference in London on July 13, 2026
July 8, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/07/08/3324070/34858/en/vaccinex-to-report-new-biomarker-data-and-plans-for-phase-2b-clinical-trial-of-pepinemab-in-ad-at-the-alzheimer-s-association-international-conference-in-london-on-july-13-2026.html
Vaccinex, Inc. Reports Financial Results for Year Ended December 31, 2025
April 29, 2026  |  quiverquant.comQ
Vaccinex Reports 2025 Annual Financial Results
April 29, 2026  |  globenewswire.comhttps://www.globenewswire.com/news-release/2026/04/30/3284388/34858/en/vaccinex-reports-2025-annual-financial-results.html
Vaccinex Inc.
April 10, 2026  |  barrons.comhttps://www.barrons.com/market-data/stocks/vcnx/company-people
Vaccinex announces $60M revenue sharing agreement with PDV
December 23, 2025  |  msn.comhttps://www.msn.com/en-us/money/other/vaccinex-announces-60m-revenue-sharing-agreement-with-pdv/ar-AA1SUmDZ
Vaccinex, Inc. Announces $60 million Agreement to Finance a Phase 2b clinical trial of pepinemab to treat Alzheimer’s Disease
December 23, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vaccinex-inc-announces-60-million-agreement-to-finance-a-phase-2b-clinical-trial-of-pepinemab-to-treat-alzheimer-s-disease-1035667359
Vaccinex, Inc. Engages in $60 Million Revenue Sharing Agreement with Pepinemab Development Venture to Advance Alzheimer’s Treatment
December 23, 2025  |  quiverquant.comQ
Vaccinex presents promising cancer treatment data at ASCO
May 29, 2025  |  uk.investing.comhttps://uk.investing.com/news/company-news/vaccinex-presents-promising-cancer-treatment-data-at-asco-93CH-4104876
Vaccinex, Inc. to Present New Data on Pepinemab's Role in Enhancing Immune Responses in Head and Neck Cancer at ASCO 2025
May 29, 2025  |  nasdaq.comhttps://www.nasdaq.com/articles/vaccinex-inc-present-new-data-pepinemabs-role-enhancing-immune-responses-head-and-neck
Vaccinex to Report Promising New Clinical Results of Neoadjuvant Treatment with Pepinemab to Enhance Immunotherapy in Patients with Head and Neck Cancer at ASCO Annual Meeting
May 27, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/05/27/3088645/34858/en/vaccinex-to-report-promising-new-clinical-results-of-neoadjuvant-treatment-with-pepinemab-to-enhance-immunotherapy-in-patients-with-head-and-neck-cancer-at-asco-annual-meeting.html
AbTherx, Inc: AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets
May 13, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-05/65384714-abtherx-inc-abtherx-single-cell-technology-and-vaccinex-announce-collaboration-to-tackle-challenging-antibody-drug-targets-200.htm
AbTherx, Single Cell Technology, and Vaccinex Announce Collaboration to Tackle Challenging Antibody Drug Targets
May 13, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/abtherx-single-cell-technology-vaccinex-100000437.html
Vaccinex to report new clinical data on pepinemab in enhancing immunotherapy
April 22, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vaccinex-to-report-new-clinical-data-on-pepinemab-in-enhancing-immunotherapy-1034603197
Vaccinex, Inc. Announces Promising Data on Pepinemab as Neoadjuvant Immunotherapy in Metastatic Melanoma and Head and Neck Cancer at AACR 2025
April 21, 2025  |  quiverquant.comQ
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)
April 21, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/04/21/3064665/34858/en/vaccinex-to-report-promising-new-clinical-data-revealing-pepinemab-s-unique-mechanism-to-enhance-immunotherapy-at-annual-meeting-of-american-association-for-cancer-research-aacr.html
Vaccinex director resigns, no disagreement cited
March 21, 2025  |  investing.comhttps://www.investing.com/news/sec-filings/vaccinex-director-resigns-no-disagreement-cited-93CH-3937856
Vaccinex plans Nasdaq exit as Alzheimer market pressure grows
March 10, 2025  |  finance.yahoo.comhttps://finance.yahoo.com/news/vaccinex-plans-nasdaq-exit-alzheimer-211545558.html
Vaccinex, Inc.: Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
March 8, 2025  |  finanznachrichten.dehttps://www.finanznachrichten.de/nachrichten-2025-03/64767350-vaccinex-inc-vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market-399.htm
Vaccinex to delist common stock from Nasdaq
March 7, 2025  |  markets.businessinsider.comhttps://markets.businessinsider.com/news/stocks/vaccinex-to-delist-common-stock-from-nasdaq-1034455385
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
March 7, 2025  |  globenewswire.comhttps://www.globenewswire.com/news-release/2025/03/07/3039274/34858/en/vaccinex-plans-to-delist-its-common-stock-from-the-nasdaq-stock-market.html

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All Headlines
Rocket Lab Electron rocket on coastal launch pad with company logo overlay, symbolizing space tech integration strategy.
Rocket Lab’s Stock Drop Comes With a Bullish Twist
By Ryan Hasson | July 10, 2026
Two Very Large Crude Carriers (VLLCs) sailing side by side on open ocean waters, viewed from above.
Strait of Hormuz Tensions Spike Tanker Trade: These 2 Stocks Are Set to Benefit
By Dan Schmidt | July 19, 2026
Exterior view of a large data center building with electrical transformers, piping, and utility equipment in the foreground.
AI’s Power Crunch Fuels a Pivot for These 2 Oilfield Stocks
By Jeffrey Neal Johnson | July 16, 2026
Data center aisle with server racks, blue lighting, and coolant supply and return pipes with gauges.
3 Stocks That Prove the AI Trade Isn't Over, It Moved
By Bridget Bennett | August 5, 2026
Aerial view of an industrial power plant and adjacent facility with the NextEra Energy logo overlaid.
Powering Up: NextEra and Brookfield Build an Off-Grid Empire
By Jeffrey Neal Johnson | July 30, 2026
CalciMedica stock logo

CalciMedica NASDAQ:CALC

$0.71 -0.03 (-3.91%)
Closing price 08/6/2026 04:00 PM Eastern
Extended Trading
$0.77 +0.06 (+8.43%)
As of 08:15 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

CalciMedica, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for illnesses caused by inflammatory and immunologic processes and direct cellular damage. The company's lead product candidate comprises Auxora, an intravenous formulated small molecule calcium release-activated (CRAC) channel inhibitors, which is in phase 2 clinical trials for the treatment of acute pancreatitis, asparaginase induced pancreatic toxicity, and acute kidney injury, as well as severe COVID-19 pneumonia. It also develops CM6336, an oral CRAC channel inhibitors for chronic inflammatory indications; and Auxora, for the treatment of acute ulcerative colitis and allergic asthma. The company is based in La Jolla, California.

Intensity Therapeutics stock logo

Intensity Therapeutics NASDAQ:INTS

$4.25 +0.05 (+1.19%)
Closing price 08/6/2026 04:00 PM Eastern
Extended Trading
$4.28 +0.03 (+0.59%)
As of 08/6/2026 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.

Kiora Pharmaceuticals stock logo

Kiora Pharmaceuticals NASDAQ:KPRX

$2.56 +0.02 (+0.79%)
Closing price 08/6/2026 04:00 PM Eastern
Extended Trading
$2.58 +0.02 (+0.98%)
As of 08:22 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.

Vaccinex stock logo

Vaccinex NASDAQ:VCNX

$1.12 0.00 (0.00%)
As of 08/5/2026

Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders. The company's lead drug candidate, pepinemab, a humanized monoclonal antibody that binds and blocks the activity of SEMA4D. It is developing Pepinemab, which is in phase 2 study for treatment of Alzheimer's disease and has completed phase 2 study for treatment of Huntington's disease; Pepinemab in combination with Pembrolizumab in phase 2 study for head and neck cancer, Avelumab in phase 2 study for pancreatic cancer, and completed phase 2 study with Avelumab for non-small cell lung cancer; and Pepinemab in combination with Nivolumab completed phase 2 study for melanoma, and trastuzumab and DC vaccine in phase 2 study for breast cancer. The company has also developed ActivMAb, an antibody drug discovery platform based on a novel method for complex targets, such as multi-pass membrane receptors or large and diverse libraries of full-length human monoclonal antibodies on the surface of pox viruses. It has collaborations with Merck Sharp & Dohme; Ares Trading S.A.; The Children's Hospital of Philadelphia; Emory University; Huntington Study Group; H. Lee Moffitt Cancer Center and Research Institute, Inc; Catalent Pharma Solutions, LLC; Surface Oncology, Inc.; and Pharmaceutical and Biotech Co. The company was incorporated in 2001 and is headquartered in Rochester, New York.

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

Stock Lists
Low Priced Stocks
Stocks By Exchange
Latest Stock Ideas